Monday, May 20, 2013

MOLECULAR STUDY X-LINKED CONGENITAL ADRENAL HIPOPLASIA (NR0B1 GENE) SEQUENCING, WHOLE BLOOD

New Test in CIC Catalog

Test Code: 4241

Sample:
Whole blood EDTA (10 ml)
Conservation:
Refrigerated
Method:
Sequencing Method
Set Up Days:
Daily
Plazo de Entrega:
32 days
Information:
X-linked adrenal hypoplasia congenita (X-linked AHC) is characterized by infantile-onset acute adrenal insufficiency at an average age of three weeks in approximately 60% of affected individuals. Onset in approximately 40% is in childhood. A few individuals present in adulthood with infertility. Adrenal insufficiency typically presents acutely with vomiting, feeding difficulty, dehydration, and shock caused by a salt-wasting episode. Primary adrenal failure characterized by hyponatremia, hyperkalemia, acidosis, and an elevated serum concentration of ACTH in the presence of normal or low serum concentration of 17-hydroxyprogesterone presenting in a male in the first month of life strongly suggests X-linked AHC. Males with such findings may have: 1) a contiguous gene deletion including the glycerol kinase gene (GK) with or without deletion of DMD, the gene encoding dystrophin (~1/3 of all affected individuals); 2) isolated AHC with a positive family history consistent with X-linked inheritance (~1/3 of affected individuals); or 3) isolated AHC with a negative family history (~1/3 of affected individuals). Individuals with a contiguous gene deletion can be identified by fluorescent in situ hybridization (FISH) using a NR0B1 (DAX1) cosmid probe or other deletion/duplication testing methods. Such testing is clinically available. Nearly 100% of affected individuals with a positive family history consistent with X-linked inheritance have an identifiable mutation in NR0B1, the only gene known to be associated with X-linked adrenal hypoplasia congenita. Between 50% and 70% of males with AHC who have no other affected family members have an identifiable mutation in NR0B1.
Links:

    Find the record of the test by clicking here

No comments:

Post a Comment